Integrated DNA Technologies (IDT), a Danaher company, has announced a strategic collaboration with Ansa Biotechnologies to expand its synthetic biology capabilities.
The partnership adds Clonal DNA and XL Clonal DNA products, ranging from 100 bp to 50 kb, to IDT’s portfolio, enabling researchers to build longer, more complex, sequence-perfect DNA constructs.
The IDT–Ansa collaboration directly addresses key bottlenecks in advanced DNA synthesis.
Core capabilities now available to IDT customers:
These capabilities support research in:
Research complexity is increasing faster than traditional DNA synthesis capabilities.
By combining strengths:
The result is a new standard for speed, precision, and reliability in long-form DNA synthesis.
Each construct is optimized and verified for:
Ajay Gannerkote, President, Integrated DNA Technologies:
“Customers face unprecedented complexity in their research. This partnership ensures they can rely on IDT across every dimension of DNA synthesis complexity.”
Jason T. Gammack, CEO, Ansa Biotechnologies:
“We were founded to solve the hardest problems in DNA synthesis—length, complexity, and reliability. Together with IDT, those barriers are coming down.”
Ansa’s proprietary platform redefines how long DNA is made.
Key advantages:
Ansa also operates under a rigorous biosecurity framework, fully aligned with the U.S. OSTP Nucleic Acid Synthesis Screening guidelines.
This collaboration reflects IDT’s evolution:
By integrating Ansa’s technology, IDT positions itself as a single partner for simple oligos to ultra-long, complex DNA constructs, accelerating translation from lab research to real-world impact.